Unknown

Dataset Information

0

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.


ABSTRACT: CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody rituximab (Rituxan), and more recently for the radiolabelled antibodies Y-90 ibritumomab tiuxetan (Zevalin) and I-131 tositumomab (Bexxar). Radiation therapy effects are due to beta emissions with path lengths of 1-5 mm; gamma radiation emitted by I-131 is the only radiation safety issue for either product. Dose-limiting toxicity for both radiolabelled antibodies is reversible bone marrow suppression. They produce response rates of 70%-90% in low-grade and follicular lymphoma and 40%-50% in transformed low-grade or intermediate-grade lymphomas. Both products produce higher response rates than related unlabelled antibodies, and both are highly active in patients who are relatively resistant to rituximab-based therapy. Median duration of response to a single course of treatment is about 1 year with complete remission rates that last 2 years or longer in about 25% of patients. Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma, and that it is a safe and efficacious modality when used as consolidation therapy following chemotherapy. Among cytotoxic treatment options, current evidence suggests that one course of anti-CD20 radioimmunotherapy is as efficacious as six to eight cycles of combination chemotherapy. A major question that persists is how effective these agents are in the setting of rituximab- refractory lymphoma. These products have been underutilised because of the complexity of treatment coordination and concerns regarding reimbursement.

SUBMITTER: Dillman RO 

PROVIDER: S-EPMC2779347 | biostudies-other | 2006 Mar

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC6343614 | biostudies-literature
| S-EPMC2805725 | biostudies-other
| S-EPMC5688039 | biostudies-literature
| S-EPMC3858978 | biostudies-literature
| S-EPMC4364776 | biostudies-literature
| S-EPMC9954594 | biostudies-literature
| S-EPMC4622538 | biostudies-literature
| S-EPMC6485963 | biostudies-literature
| S-EPMC4865612 | biostudies-literature
| S-EPMC2234056 | biostudies-literature